About Shasqi

Shasqi is a privately held, clinical stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies. Shasqi leverages its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform to develop precision activated oncology therapeutics designed to improve efficacy while decreasing systemic toxicity. Shasqi’s CAPAC Platform is highly modular and can be applied to a broad range of drugs that are otherwise limited by toxicity, enabling the exploration of therapeutic biology in ways that were not previously possible.

Shasqi and CAPAC™ Origins

Shasqi

Definition: \'shas-kē\ Noun. [fr. Quechua, ca. 1400‘s, also Chasqui, Chaski]

1. Hist. System of agile runners created to communicate and distribute goods across large distances. One of the components that enabled the rise of a vast Incan Empire.

2. A way to activate cancer drugs at specific areas of the body.

CAPAC

Definition: \'qhapaq’\ Noun. [fr. Quechua, ca. 1400‘s, also qhapaq]

1. Mighty, powerful, noble.

2. Click Activated Protodrugs Against Cancer (CAPAC™). A new platform to improve cancer therapies.

Leadership

José M. Mejía Oneto, MD, PhD

Founder & Chief Executive Officer

Wayne Saville, MD

Chief Medical Officer

Sebastian Sanchez de Lozada

Chief Financial Officer

Board of Directors

José M. Mejía Oneto, MD, PhD

Juan Jaen, PhD

Strategic Advisors

Ronald W. Barrett, Ph.D.

CEO at Medikine

Carolyn Bertozzi, Ph.D.

Professor at Stanford

Lisa M. Coussens, Ph.D., FAACR

Professor & Department Chair at OHSU

Sarah Noonberg, M.D., PH.D.

Chief Medical Officer at Maze Therapeutics

Pamela M. Klein, M.D

Chief Medical Officer at Olema

Lawrence D. Mayer, Ph.D.

Partner at Coulour Biomedical

Glenn Prestwich, Ph.D.

Co-founder at Spinout Space

William J. Rieflin

Executive Chairman at NGM Bio

Nina Shapiro

Sr. Operating Advisor at New Silk Route